© 1994 British Society for Rheumatology
research-article |
INTERMITTENT CYCLICAL ETIDRONATE IN THE PREVENTION OF CORTICOSTEROID-INDUCED BONE LOSS
*Gezondheidscentrum Zuidplein Metroplein 50, 3083 BB Rotterdam, The Netherlands
Sint Clara Hospital Olympiaweg 350, 3075 HT Rotterdam, The Netherlands
We conducted a prospective study of etidronate's effects on corticosteroid-induced bone loss in postmenopausal women with temporal arteritis for whom high-dose prednisone therapy was indicated. Group A (n=10) received etidronate (400 mg/day for 2 weeks, then 11 weeks off etidronate; four cycles total) and prednisone; Group B (n=10) received only prednisone. Vertebral bone mineral density (BMD) was measured blinded by dual X-ray absorptiometry.
At 3,6 and 12 months, vertebral BMD was significantly (P<0.01) increasedin Group A and decreased in Group B, based on mean actual and percent changes in BMD and mean changes in BMD Z-score from baseline. Between-group comparisons were also significant (P<0.002) at each time point. No adverse events related to etidronate treatment were reported.
Our results suggest that corticosteroid-induced bone loss may be prevented by instituting intermittent cyclical etidronate therapy when high-dose prednisone therapy is begun. Further research into bisphosphonate use in corticosteroid-induced bone loss (with larger patient populations, longer follow-up and fracture assessment) is warranted.
KEY WORDS: Bone loss, Corticosteroids, Etidronate, Prednisone, Temporal arteritis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I A Campbell, J G Douglas, R M Francis, R J Prescott, and D M Reid Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids Thorax, September 1, 2004; 59(9): 761 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Brown and R. G. Josse Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'osteoporose au Canada Can. Med. Assoc. J., March 18, 2003; 168(90060): SF1 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Brown and R. G. Josse 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada Can. Med. Assoc. J., November 12, 2002; 167(90100): s1 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Yeap and D. J. Hosking Management of corticosteroid-induced osteoporosis Rheumatology, October 1, 2002; 41(10): 1088 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Conron and H. L C Beynon Rare diseases bullet 11: Churg-Strauss syndrome Thorax, October 1, 2000; 55(10): 870 - 877. [Full Text]
|
|
|
|
|
|
A. Struijs, A. Smals, S. A. de Witte, W. H. L. Hackeng, and H. Mulder Acute effects of etidronate on glucocorticoid-induced bone degradation Rheumatology, May 1, 2000; 39(5): 523 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Pfeilschifter and I. J. Diel Osteoporosis Due to Cancer Treatment: Pathogenesis and Management J. Clin. Oncol., April 7, 2000; 18(7): 1570 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E M Scott, I Gaywood, and B B Scott Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease Gut, January 1, 2000; 46(90001): I1 - 8. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Geusens, J. Dequeker, J. Vanhoof, R. Stalmans, S. Boonen, J. Joly, J. Nijs, and J. Raus Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study Ann Rheum Dis, December 1, 1998; 57(12): 724 - 727. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Roux, P. Oriente, R. Laan, R. A. Hughes, J. Ittner, S. Goemaere, O. Di Munno, J. M. Pouillès, S. Horlait, and B. Cortet Randomized Trial of Effect of Cyclical Etidronate in the Prevention of Corticosteroid-Induced Bone Loss J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1128 - 1133. [Abstract] [Full Text]
|
|
|
|
|
|
J. W J BIJLSMA Prevention of glucocorticoid induced osteoporosis Ann Rheum Dis, September 1, 1997; 56(9): 507 - 509. [Full Text]
|
|
|
|
 |
|
 J. D. Adachi, W. G. Bensen, J. Brown, D. Hanley, A. Hodsman, R. Josse, D. L. Kendler, B. Lentle, W. Olszynski, L.-G. Ste.-Marie, et al. Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis N. Engl. J. Med., August 7, 1997; 337(6): 382 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. F Lems, J. W G Jacobs, J. W J Bijlsma, G. J M van Veen, H. H M L Houben, H. C M Haanen, M. I Gerrits, and H. J M van Rijn Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? Ann Rheum Dis, June 1, 1997; 56(6): 357 - 363. [Abstract] [Full Text]
|
|
|
|
 |
|
 Corticosteroid-induced osteoporosis DTB, November 1, 1996; 34(11): 84 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L J Walsh, C A Wong, M Pringle, and A E Tattersfield Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study BMJ, August 10, 1996; 313(7053): 344 - 346. [Abstract] [Full Text]
|
|
|
|
|
|
J E Compston Fortnightly Review: The therapeutic use of bisphosphonates BMJ, September 17, 1994; 309(6956): 711 - 715. [Full Text]
|
|